Literature DB >> 7695977

Hepatic resection for metastases from colorectal carcinoma--a survival analysis.

G R Jatzko1, P H Lisborg, H M Stettner, M H Klimpfinger.   

Abstract

Between 1 January 1984 and 31 December 1992, 66 patients with hepatic metastases from colorectal carcinomas underwent liver resection. 40 of these patients had synchronous hepatic metastases, and liver resection was carried out simultaneously with radical resection of the primary tumour; in 26 cases metachronous metastases in the liver were surgically removed. 25 patients had an anatomical resection and the remainder underwent atypical resections. The postoperative mortality rate was 4.5% and the major complication rate was 19.7%. Univariate and subsequently multivariate analyses were used to predict the influence of various clinical, histopathological and surgical variables. The observed 5-year survival rate was 29.6% and the 5-year disease-free survival rate 13.9%. Furthermore, the observed median survival time was 24.7 months and the mean disease-free survival time was 16.7 months. Multivariate analysis showed that stage of primary (pTN) (P = 0.043), tumour grading (P = 0.013) and site of primary (P = 0.007) were factors which independently influenced 5-year disease-free survival whereas stage of primary (pTN) (P = 0.008), tumour grading (P = 0.004) and type of resection (P = 0.035) were identified as having independent influence on 5-year observed survival. We consider liver resection to be an effective form of treatment for patients with resectable liver metastases from colorectal carcinoma, although the overall chances for cure are generally not very promising. It appears that the biological behaviour of the primary tumour, in terms of tumour stage and grading, has the greatest influence on survival.

Entities:  

Mesh:

Year:  1995        PMID: 7695977     DOI: 10.1016/0959-8049(94)00366-d

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

Review 1.  Resection of colorectal liver metastases revisited.

Authors:  J Scheele; C Rudroff; A Altendorf-Hofmann
Journal:  J Gastrointest Surg       Date:  1997 Sep-Oct       Impact factor: 3.452

2.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.

Authors:  V O Chan; J P Das; J F Gerstenmaier; J Geoghegan; R G Gibney; C D Collins; S J Skehan; D E Malone
Journal:  Ir J Med Sci       Date:  2012-03-17       Impact factor: 1.568

3.  Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer.

Authors:  Jeong Won Lee; Seok-Ki Kim; Sang Mi Lee; Seung Hwan Moon; Tae-Sung Kim
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

4.  Fas/CD95 signaling rather than angiogenesis or proliferative activity is a useful prognostic factor in patients with resected liver metastases from colorectal cancer.

Authors:  Hisashi Onodera; Akira Mori; Satoshi Nagayama; Akihisa Fujimoto; Tsuyoshi Tachibana; Yoshikuni Yonenaga; Tatsuaki Tsuruyama
Journal:  Int J Colorectal Dis       Date:  2005-04-22       Impact factor: 2.571

5.  Analysis of predictive factors for recurrence after hepatectomy for colorectal liver metastases.

Authors:  H Yamada; S Kondo; S Okushiba; T Morikawa; H Katoh
Journal:  World J Surg       Date:  2001-09       Impact factor: 3.352

6.  Prognostic significance of entrapped liver cells in hepatic metastases from colorectal cancer.

Authors:  M Koike; K Yasui; A Torii; S Kodama
Journal:  Ann Surg       Date:  2000-11       Impact factor: 12.969

7.  Pre-hepatectomy prognostic staging to determine treatment strategy for colorectal cancer metastases to the liver.

Authors:  Kuniya Tanaka; Hiroshi Shimada; Yoshirou Fujii; Itaru Endo; Hitoshi Sekido; Shinji Togo; Hideyuki Ike
Journal:  Langenbecks Arch Surg       Date:  2004-07-03       Impact factor: 3.445

8.  Superiority of combined chemo-embolization and portal infusion with 5-fluorouracil over locoregional infusion concepts in Novikoff hepatoma-bearing rats.

Authors:  Hermann Bödeker; Ernst-Jan Kamphorst; Peter H Wünsch; Ulrich Linnemann; Martin R Berger
Journal:  J Cancer Res Clin Oncol       Date:  2003-09-26       Impact factor: 4.553

9.  Structural basis of antifolate recognition and transport by PCFT.

Authors:  Joanne L Parker; Justin C Deme; Gabriel Kuteyi; Zhiyi Wu; Jiandong Huo; I David Goldman; Raymond J Owens; Philip C Biggin; Susan M Lea; Simon Newstead
Journal:  Nature       Date:  2021-05-26       Impact factor: 49.962

Review 10.  Unresolved issues and controversies surrounding the management of colorectal cancer liver metastasis.

Authors:  Woubet T Kassahun
Journal:  World J Surg Oncol       Date:  2015-02-18       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.